Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShares Issued
Growth Metrics
Income Statement
Others
Ratios

Skinvisible (SKVI) Capital Expenditures (2018 - 2025)

Skinvisible (SKVI) has disclosed Capital Expenditures for 7 consecutive years, with -$1.0 as the latest value for Q3 2025.

  • Quarterly Capital Expenditures changed N/A to -$1.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$1.0 through Dec 2025, changed 0.0% year-over-year, with the annual reading at $4086.0 for FY2025, 55.67% down from the prior year.
  • Capital Expenditures hit -$1.0 in Q3 2025 for Skinvisible, roughly flat from -$1.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $20414.0 in Q2 2021 to a low of -$1.0 in Q3 2023.
  • Historically, Capital Expenditures has averaged $4388.7 across 4 years, with a median of $525.0 in 2022.
  • Biggest YoY gain for Capital Expenditures was 47.9% in 2021; the steepest drop was 48.28% in 2021.
  • Year by year, Capital Expenditures stood at $20414.0 in 2021, then plummeted by 97.43% to $525.0 in 2022, then tumbled by 100.19% to -$1.0 in 2023, then changed by 0.0% to -$1.0 in 2025.
  • Business Quant data shows Capital Expenditures for SKVI at -$1.0 in Q3 2025, -$1.0 in Q3 2023, and $8809.0 in Q2 2023.